Life Sciences Archive » August, 2014

Life Sciences - August, 2014

307 articles

• $3B Lilly Case Spotlights Drug Promoters' Labeling Quandary
• Ex-Arthrocare CEO Gets 20 Years In $756M Fraud Case
• Texas High Court Won't Overturn Fraudster's Disbarment
• IPO Filings Soar In Late-August Heat
• Sandoz's Remodulin Generic Infringes UTC Patent, Judge Says
• Feds Rip PhRMA's Free Speech Claims In FCA Off-Label Suit
• Takeda Challenges Claim Construction Rule At High Court
• Taxation With Representation: Gibson Dunn, Cravath, Wachtell
• Boston Scientific Wins 2nd Pelvic Mesh Bellwether Trial
• Dealmakers Q&A: WilmerHale's Brian Johnson
• 5 Reasons Large Companies Are Turning To Boutique Firms
• Ebola, ZMapp, And The §101 Guidance
• How To Protect In-House Legal Privilege Internationally
• More Deals Expected This Fall As Economy Pushes M&A Surge
• Takeda, Eli Lilly Stuck With $9B Actos Verdict
• Prestige Must Shed Bonine To Win FTC Nod On $750M Deal
• Apotex Says Generic Paxil Suit Should Be Tossed
• Lannett Faces Shareholder Suit Over Price-Fixing Scheme
• Inventor Fires Back At Patterson Belknap In Surgical IP Row
• Novartis Hits Zydus With Patent Suit Over Dementia Patch
• CMS Gets Heat On Elimination Of Sunshine Act Exemption
• Two More Biotechs Enter IPO Pipeline, One Revives Plans
• Seeking Retrial, Stock Scheme Atty Says Gov't Hid SEC Docs
• Perils Of Communicating With Customers By Phone Or Text
• India Enters The 'Pay-For-Delay' Fray
• 3 Biotechs Join IPO Pipeline, Suggesting Window Still Open
• PhRMA Asks Medicare To Clear Up Sunshine Act Headaches
• The 5 Biggest M&A Moves Of The Summer
• Anda Contradicts Itself In 'Pill Mill' Suit, Insurer Says
• Drugmakers Fight Doc Request In MDL Over Diabetes Drugs
• Skadden Reps JLL Partners-Backed Co. In Biopharma Deal
• Chancery Fast-Tracks Ackman Suit To Force Allergan Meeting
• PhRMA Must Restart Suit Over 340B Orphan Drug Rule
• Philly Mesh Suits Face Uncertainty After Sole Pa. Co. Axed
• Post-AbbVie: Written Description And Functional Claiming
• Allergan Sets Special Meeting In $53B Valeant Takeover Bid
• Salix Investor Challenges $2.7B Inversion Deal With Cosmo
• Appeals Court Nixes Arbitration In Avandia Fee Row
• Virtus, Pamlab Settle Vitamin B False Ad Row In Fla.
• Biotech Co. Zosano Puts IPO Plans On Hold
• Fed. Circ. Told To Nix En Banc Bid In Bristol-Myers IP Case
• FDA Details Stance On Questions From Generics Makers
• Chancery Won't End Astex Buyout Case, Citing Lack Of Notice
• 3rd Circ. Won't Revive Watson Fertility Drug Ad Suit
• Generic Cos. Back On Hook In Reglan Failure-To-Warn Case
• Browne George Gets Arbitration For Sargon Malpractice Suit
• NAFTA Board Tosses $520M Apotex Case Over FDA Import Ban
• Mylan Needn't Recall Generic Precedex In Battle With Hospira
• Pfizer, AstraZeneca Stay Quiet As Cooling-Off Period Ends
• Zimmer Wants Sanctions Against Knee Implant MDL Attorneys
• Teva, AstraZeneca Say Court Rulings Kill Nexium Delay Suit
• Gilead And Potential Unforeseen Consequences: Part 2
• J&J Noncompete Suit On Thin Ice With Worker's Claims Nixed
• Philips Beats Zoll's Challenge To 8 Patents In Fed. Circ.
• Actavis Can't Sell Generic Gralise After Depomed IP Trial
• Virtus Seeks Mistrial In Pamlab's Vitamin B False-Ad Row
• Hospira Rebuts 7th Circ. Rebuke In Worker Retaliation Suit
• Plasma Firms Can't Dodge Calif. Antitrust Claims
• Fresenius Loses Diprivan IP Suit Against Actavis, Dr. Reddy's
• Biotech Co. Preps For IPO, But May Delay Again
• Feds Seek 30 Years In Prison For ArthroCare CEO, 20 For CFO
• Shire Urges High Court Review Of Claim Construction Rule
• Valeant, Ackman Launch Suit Pushing For Allergan Meeting
• Using Post-Grant Proceedings To Challenge Pharma Patents
• 4 Trends In FTC Antitrust Regulation And Enforcement
• Gilead And Potential Unforeseen Consequences: Part 1
• Davis Polk Guides Roche In $8.4B Respiratory Drugmaker Buy
• Judge Won't Toss GSK IP Suit After High Court's Alice Ruling
• Bristol-Myers, Otsuka Hit With Failure-To-Warn Suit For Abilify
• 3 Companies Join IPO Pipeline As Others Take A Step Back
• Corning Doesn't Infringe DSM Fiber Optics Patents, Suit Says
• Sandoz Denied Prosecution Bar In Cardene Patent Row
• Brand Battles: Sherlock Holmes, Seattle Seahawks, The Hobbit
• Fed. Circ. Sides With Generics Makers In Lysteda IP Suits
• Ex-SAC Trader Says 8-Year Sentence Would Be Overly Harsh
• Why AstraZeneca Is Likely On Pfizer's Back Burner, For Now
• Judge Trims Intuitive Surgery Device Securities Class Action
• Transitions Wants Rival's Claims Tossed From Antitrust MDL
• Valeant, Ackman Request Allergan Special Meeting
• FedEx Board Sued Over DOJ Drug Investigation
• Howmedica Sales Reps. Win Cert. In Reimbursement Suit
• ​Tackling Pot Law A Niche Practice As Some Firms Shy Away
• Dealmakers Q&A: Bird & Bird's Alberto Salvade
• Inter Partes Review's Day Has Come For Pharma IP Cases
• Allergan Suit May Not Stop Meeting To Replace Board
• Purdue Wants Cohen Milstein Atty DQ'd In Chicago Opioid Row
• 1st Circ. Allows FCA Defendants To Push For Tax Breaks
• Whole Foods Slapped With $5M Homeopathy Class Action
• DEA Clamps Down On Hydrocodone Combo Medications
• Deals Rumor Mill: Pfizer, American Tire, VakifBank
• Fed. Circ. OKs AbbVie's Double-Patenting Win In Humira Case
• FDA Approves Covidien's Fixes To Recalled Pipeline Devices
• FDA Unveils Action Plan For Clinical Trial Demographics
• Dr. Reddy's Child-Resistant Drug Packs Under CPSC Scrutiny
• AKS Unlikely To Be Raised Over Pharma Discount Sales
• How To Control Risk And Cost Of E-Discovery
• IP In A Financial Center: Ireland Vs. Cayman Islands
• Plain Prosecution Bar May Not Cover Inter Partes Reviews
• Inside 2nd Circ. Ruling On Overseas Whistleblower
• Fed. Circ. Urged Not To Review Mandate Ruling In $5M IP Row
• Deal Ending $7M Fen-Phen Referral Fee Row May Be Near
• Novartis Gets Zometa Jaw Injury Suit Thrown Out In Calif.
• Deals Rumor Mill: Mylan, Lear, Iliad
• Nexium Buyers Say Ranbaxy Should Turn Over Docs In MDL
• Generic-Drug Consumers Get Rare Boost With Ala. Ruling
• Glenmark Ducks Class Action Over Birth Control Packaging
• 5 Bold Moves Shaping Valeant's Epic Fight For Allergan
• Valeant Says Allergan Lied To Obstruct $53M Takeover
• Mylan Wins Stay Of Generic Precedex Recall In Hospira Row
• Kilpatrick Townsend Adds Life Sciences Partner In Seattle
• 8th Circ. Provides Guidance On FCA Public Disclosure Bar
• Hospira Sues FDA Over Generic Precedex Carve-Out Approval
• Apotex Case Shows Inequitable Conduct Is Still A Potent Tool
• Nautilus Says High Court Indefiniteness Test Kills Biosig Patent
• Tech Cos. Urge High Court To Keep Claim Construction Rule
• FDA Rips Nidek Again On Quality Control Lapses
• High-Profile Fights For Control Showcase Seller's Market
• Allergan Eyes Salix Tie-Up To Thwart $53B Valeant Takeover
• IRS' Med Device Tax Collection Needs Revamp, TIGTA Says
• Apotex's Claim Of Provigil Monopoly To Be Decided At Trial
• AstraZeneca Says DOJ Closing Probe Into Brilinta Trial
• Teva Atty Says He Was Axed Over Family-Support Payments
• Sponsors Should Mind FDA Informed Consent Guidance
• Medtronic Reaffirms $43B Covidien Bid Despite Opposition
• 6th Circ. Revives Aredia Jaw Injury Suit Against Novartis
• FDA Rejects Ex-Staffer's Call To Pull Lasik Devices
• Deals Rumor Mill: Telecom Italia, ConvaTec, SoftBank
• Walgreen Ducks FCA Suit Over Alleged Medicare Overbilling
• IMS Health Rival Can't Duck Poaching Claims In Antitrust Feud
• 6 Tips For FCA Plaintiffs Snubbed By DOJ
• JPML Urged To Ship 28 Cymbalta Suits To California
• Zimmer Protests $79M IRS Transfer Pricing Assessment
• PhRMA Says Integrilin FCA Suit Stifles Free Speech Rights
• Novo Fined For Delaying News Of FDA's Blocking Of Drug
• 2 IPOs Planned This Week As Slow August Continues
• Valeant Giving Allergan Until End Of Year To OK $53B Buyout
• Chugai Denies $10B Roche Takeover Talks
• Fed. Circ. Nixes Apotex Patent For Inequitable Conduct
• MFV Urges High Court To Revive Medtronic Patent Dispute
• Brothers Can't Skirt Insider Trading Verdict Over Chattem Sale
• Gilead Wins Rights To Hep C Drug In Roche Patent Dispute
• Ex-Virginia Gov. McDonnell, Wife Denied Acquittal At Trial
• Deals Rumor Mill: Roche Holding, Arcapita Bank, Shake Shack
• Employee Secrecy Pacts Don't End Whistleblower Threat
• ABL Asks High Court To Let Invalidated Patents Get 2nd Look
• GSK Appeals Mylan Trial Victory Over Generic Paxil Deal
• Generics Lobby Not Fully Sold On FDA Biosimilars Guidance
• Ala. High Court Upholds Landmark Generic-Drug Injury Ruling
• Sen. Durbin Fires Off Inversion-Shaming Letter To Hospira
• CMS Rejects 1/3 Of Sunshine Act Disclosures, Threatens Fines
• UK Clears Cancer Testing Merger On Firm's Financial Woes
• Davita Calls Whistleblowers' FCA Kidney Drugs Suit Flawed
• FedEx Faces Money Laundering Counts In Drug Shipping Case
• Dechert, Mayer Brown Allowed To Collaborate On AIA Reviews
• Valeant Calls Allergan's Insider Trading Claims A Stunt
• An In-House Lawyer's Top 10 Tips For Outside Counsel
• What's More Unnatural Than A Clone?
• Boston Scientific Begins 2nd Mesh Bellwether Trial In Mass.
• Sandoz, Mylan Ask Justices To Affirm Teva Patent Invalidation
• 2nd Circ. Ruling On Overseas Tipsters Dodges Big Issues
• Recall Report: GM, Amgen, McCormick
• FDA Warns Public About Online Ebola Remedy Scams
• Distributor Sues Biz Partner Over FDA Alert, IP Row
• Deals Rumor Mill: Allergan, Electrolux, Axalta
• Medtronic Shakes Most Claims In Bone Device Injury Suit
• Reed Smith Atty's Widow Slams GSK's 'Invasive' Subpoena
• FDA Guides Biologics Makers On Safety Evaluations
• MiMedx Stock Rebound Doesn't Sink Shareholder Suit
• Impax Hit With Investor Class Action After FDA Criticism
• Allergan Makes $588M Acquisition Play Amid Valeant Fight
• Dodd-Frank Doesn't Shield Whistleblowers Overseas: 2nd Circ.
• Dealmakers Q&A: Irell & Manella's Gregory Klein
• Judge Won't Toss SAC Insider Trading Class Action
• Big Data Can Yield Big Insights On Promotional Practices
• Medtronic Ruling Creates Hurdles For Antitrust Defendants
• PhRMA, BIO Open Fire On FDA's Biosimilars Guidance
• SAC Ordered To Hand Over SEC Docs In Insider Trading Suit
• Attorneys Want $3M Fee In Skelaxin Antitrust Row
• FDA Outlines Simpler Approvals For Novel Devices
• FDA Issues Guidance On Unique Device IDs For Small Biz
• SEC Wins Asset Freeze In Pot Stock Pump-And-Dump Case
• Law Firms May Be Violating Copyrights
• 5 Tips For Internal False Claims Act Investigations
• Novak Druce Adds 4 Attys To Houston And Calif. Offices
• Otonomy Raises $100M In Public Debut To Back Ear Treatment
• Dealmakers Q&A: Ungaretti & Harris' Brian Krob
• Dealmakers Q&A: Nixon Peabody's Michele Masucci
• 7th Circ. Warns Attys To Keep Dismissal Bids Spin-Free
• Pfizer Wins Exclusion Of More Experts In Zoloft MDL
• Boston Scientific Atty Fatally Shot, Partner Suspected
• FTC Sends Allergan, Valeant Second Info Request
• Pharmacies Grapple With Surge Of FCA Suits
• Vitamin C Makers, Buyers Fire Closing Salvos In 2nd Circ.
• Drug Developer Geno Ditches IPO Amid Rocky Biotech Market
• Cubist Acquisition Payments Targeted In FCPA Probe
• Ex-Integra Employees Cop To $800K Overbilling Fraud
• J&J Seeks To Boot Suit Claiming Baby Powder Causes Cancer
• Fed. Circ. Won't Reconsider Dolly Clone Patent Ruling
• JPML Won't Centralize Mirena Injury Suits Against Bayer
• JPML Refuses Consolidation Of Endo Birth Control Suits
• AstraZeneca Loses Generic Crestor Challenge In Australia
• Endo, Impax Face Yet Another Suit Over Opana Pay-For-Delay
• Covidien Faces New Investor Suit Over $43B Medtronic Deal
• Vascular Biogenics IPO Undone After Investor Fails To Buy
• Dealmakers Q&A: Gibson Dunn's Stephen Glover
• A Close Look At NY's New Privilege Log Rule
• Hot Boston Legal Market A Boon For Bingham Merger Hopes
• ITC Reverses Burden Of Proof In Sleep-Aid Patent Dispute
• New Bill Floats Sweeping Medicare Fraud Reforms
• Industry Holds Breath As FDA Weighs Remicade Biosimilar
• Forward Pharma Plans $200M IPO To Back Drug Development
• FDA To Allow Vitamin D3 In More Meal Replacement Shakes
• Questcor Must Face Infantile Spasm Drug Antitrust Suit
• Quiet Week Expected With 4 IPOs Amid August Slowdown
• Gilead Wants Finnegan DQ'd In Hepatitis Drug IP Row
• AIA Review Of Wyeth's Tygacil Sought By Drug-Pricing Group
• Pelvic Mesh Part Maker Should Be Freed From Suit, Judge Told
• Taro Settles With Texas For $19.5M Over Medicaid Claims
• Athena Claims Federal Preemption In Eyelash Product Fight
• PharmAthene Wins Damages For Lost Profits In SIGA Row
• Faulty Data Shakes Faith In Sunshine Act Rollout
• McKesson To Pay $18M To End CDC Drug Shipment Claims
• SAC, Cohen Say Investors Unharmed By Alleged Inside Trades
• China Convicts US, British Investigators On Privacy Charges
• NuScience Can't Base IP Suit On One Sale, 9th Circ. Told
• Both Sides Score Evidence Wins In Transvaginal Mesh Case
• Eisai Sues FDA To Reclaim Lost Exclusivity For 2 Drugs
• GSK Paxil Birth Defect Suit Remanded To Calif. State Court
• CVS Looks To Ax False Labeling Suit Over Vitamin E Pills
• $1B Bard Graft Patent War Must End, Gore Tells Fed. Circ.
• Novartis Gets Whistleblower Kickback Suit Pared
• Google To Spend $250M To End Investor Suit Over Pharma Ads
• How Pot Businesses Can Make Your Property Go Up In Smoke
• FTC V. Cephalon — The Actavis Fray Begins
• Compliance Reigns Supreme As In-House Demographics Shift
• Divisive IP Ruling May Mean New Antitrust Liability — Or Not
• Illumina Can't Dodge Ariosa Counterclaims In DNA Test Fight
• Reckitt Stiffed Us On Mucinex Supply Deal, Generic Cos. Say
• 6th Circ. Says Stryker Owes Insurer $2M In Bad Knee Row
• Becton Says Fed. Circ. Misapplied 'Mandate Rule'
• CMS Extends Window For Sunshine Act Pay Verification
• Brazil Fines Merck $1.8M Over Plot To Block Generics
• New FDA Rules Are Boon To Medical Mobile App Developers
• Fidelity Dumps Valeant Shares In Thick Of Allergan Assault
• Roxane Loses Bid To Block Hetero's Generic Kidney Drug
• Public Reports Save Stryker From FCA Suit At 8th Circ.
• FTC Seeks More Docs From Medtronic Over $42B Covidien Buy
• Biotech IPO Market Wavers As 2 Postpone, 1 Falls Short
• Collaboration In The Shadow Of The Billable Hour
• K&L Gates Nabs Ex-Baker & McKenzie Life Sci, M&A Pro
• Lot Of Inversion Talk, But Do You Know The Basics?
• St. Jude's, Amgen Settle Cancer Research Patent Row
• US Attorney Questions Boston Scientific's BridgePoint Buy
• Shire Seeks To Ax Adderall Antitrust Class Action In Fla.
• IG Flags $32M Paid By Medicare In Suspect HIV Drug Sales
• Fed. Circ. Revives Patent Antitrust Claims Against Tyco
• Most Of Med Device Sales Trade Secrets Suit Survives
• Mich. High Court Buries CVS, Rite Aid Generics FCA Suits
• Fed. Circ. Revives ScriptPro Pill-Dispenser Patent Suit
• Target, Pfizer, Others Voice Support For Gay Marriage
• Proxy Advisers Slam Allergan, Support Shareholder Meeting
• Galderma Sued Over Patent Sale Agreement For Skin Drug
• Abbott Won't Appeal 9th Circ. Gay Juror Decision in GSK Row
• NAD Snuffs Merck's Objections To Sanofi Nasal Spray Claims
• 2nd Circ. Throws Out Appeal Of Lipitor FCA Dismissal
• NuVasive Can't Duck $30M Verdict In Neurovision TM Row
• Pfizer Pays $35M To Settle AGs' Rapamune Marketing Probe
• Class Cert. Denied In TCPA Suit Against Medtox Scientific
• Feds Charge Biogenesis Exec, Others In MLB Doping Scandal
• 10th Circ. Revives Medtronic Bone Mill Antitrust Case
• Stock Pushers Charged After SEC Pot Pump-And-Dump Probe
• Ex-Manager For NJ Pharma Co. Accused Of Embezzlement
• FDA Outlines Distinct Risks Of At-Home Medical Devices
• AMA, Medical Groups Decry Sunshine Act Database Launch
• Takeda Barred From Doubling Up Patent Claims In Drug Case
• Class Action Atty On Hook For $42M Fen-Phen Judgment
• Allergan's Valeant Suit Could Be Landmark Securities Case
• Norton Rose Fulbright Survives DQ Bid In Pamlab Suit
• AOPA Suit Over Medicare Prosthetics Payment Rule Tossed
• Auris Medical Cuts Expected IPO To $56M
• Allergan Continues Assault On Valeant Disclosure Policy
• 5 Takeaways From FDA Medical Device Data System Guidance
• Baby Sex Prediction Co. Tells 9th Circ. Calif.'s Suit Is Barred
• CORRECTED: NuVasive Seeks New Trial In Bid To Nix $30M IP Verdict
• Roche Win Upheld In 'Twin Peaks' Star's Accutane Case
• 9th Circ. Keeps Fentanyl Death Suit In Federal Court
• FTC OK's $324M Akorn Deal For Drugmaker, With Conditions
• Deals Rumor Mill: TPG, Gables, GlaxoSmithKline
• 'Sugar Pill' Buyers Win Class Cert. In Homeopathy Suit
• Kromann Advises Roche On $450M Santaris Buy
• FDA Set To Release Biosimilars Naming Guidance, Sens. Say
• Puritan's Pride Prevails In Tissue Regeneration Patent Brawl
• Medical Device Equivalence Analysis Examines 2 Factors
• Verein Tie-Ups Gain Allure As Firms Eye Global Expansion
• UK Firms Expand Global Empire, But US Firms Gaining Ground
• Law360's Global 20 Firms Take Global To New Heights
• SmartGene Says IP More Abstract Than Alice, Mayo Claims
• USPTO Warned New Eligibility Rules Put Patents At Risk
• Novak Druce Expands To Philly With Blank Rome IP Atty
• Fed. Circ. Nixes Rehearing Bids In Colon Cleanser Patent Row
• McKenna Long Loses Bid For Sanctions In Malpractice Row
• Aruba Networks Exec Has Plan To Limit Patent Bill To Trolls
• Deals Rumor Mill: CorePharma, Awas, SMBC
• AstraZeneca Sues Zydus To Block Generic Nexium
• Allergan Alleges Insider Trading Between Valeant, Ackman
• FDA Frees Wide Range Of Devices From Oversight
• Canadian Limits On Cooperation With Foreign Courts